Proceeds from the financing will be used to expand the deployment of the companys digital pathology software and accelerate the use of artificial intelligence (AI) applications to drive accuracy and efficiency in cancer diagnosis. The capital raised will fuel the development and commercialization of new, clinical AI-enabled workflows targeting high-volume, high-impact cancers, the first of which will be available later this year. Proscia will also use the funds to ramp up sales and marketing of its existing cloud-based digital pathology platform, which will serve as the foundation for Proscias AI-based applications. Combined, these technologies will redefine the field of pathology and be the impetus that moves human healthcare forward.

Digital pathology and artificial intelligence are unlocking new possibilities for pathologists in the fight against cancer, said David West, CEO at Proscia. Pathology has been historically underserved by technology, and we believe that powerful software tools will push the boundaries of how modern pathology is practiced. Thats why this funding is so important. It will allow us to expand the adoption of digital pathology, while creating intelligent systems that will unlock data from tissue to greatly enhance pathologists productivity, increase access to care, and improve the way cancer is researched, diagnosed, and ultimately treated.

Pathology is at the center of cancer diagnosis and guides a patients entire cancer journey, yet pathologists, and their ability to diagnose cancer, are largely dependent on the microscope that has been in place for 150 years. The limitations of the microscope and the subjectivity involved in assessing tumors contribute to diagnostic error, resulting in negative patient outcomes and economic burden to the healthcare system. Proscia represents a paradigm shift, using the image analysis capabilities of machines to augment human evaluations for better, more reliable diagnosis. Facing intense economic pressure, a shrinking workforce, and a surge in the global demand for pathology, laboratory medicine is primed for a shift to digital and AI-driven methods.

Subscribe to the Global Banking & Finance Review Newsletter for FREE Get Access to Exclusive Reports to Save Time & Money

By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information. All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

Adopt digital pathology on their own terms by rolling out new features and capabilities seamlessly as they embark on the path to AI-enhanced pathology

This robust platform will serve as the launchpad for a series of AI-enabled, disease-specific modules, the first of which, DermAI„¢, will be released in December 2018.

Chip Hazard, General Partner at Flybridge, commented on Proscias unprecedented momentum in the digital pathology space. David and his team are exactly the kind of entrepreneurs Flybridge believes can develop innovative solutions for customers, unlock stunning growth, and become category leaders. In addition to creating platform-agnostic software that is modernizing commercial labs, academic medical centers, and hospitals, Proscia is pioneering worlds-first advancements in deep learning that have the potential to change cancer research.

As part of the funding, Chip Hazard and Tom Loftus, Chief Technologist at Razors Edge Ventures, have joined Proscias Board of Directors.

For more information or a demo of Proscias digital pathology platform, to discuss partnership opportunities, or to join our team, contact Proscia at www.proscia.com/contact.

About Proscia

Proscia was founded in 2014 by a team out of Johns Hopkins and the University of Pittsburgh to improve clinical outcomes and accelerate the discovery of breakthrough advancements in the fight against cancer. Using modern computing technologies that unlock hidden data not visible to the human eye and turning that data into valuable insights in the fight against cancer, the company is dedicated to improving the efficiency, speed and quality of pathology diagnostics and research. www.proscia.com

About Flybridge

Flybridge is a seed and early-stage venture capital firm with offices in Boston and New York City whose mission is to partner with talented entrepreneurs to build exceptional and valuable technology companies. With $625 million under management across four funds, the firm has invested in more than 120 companies across the machine learning, artificial intelligence, Blockchain, cybersecurity, infrastructure and future of work markets and is led by a team with more than a century of combined experience as investors and entrepreneurs. www.flybridge.com